FDA Clears AI-Powered Cardiovascular Ultrasound System from Siemens Healthineers
Offering a variety of AI features for streamlined workflow and enhanced visualization, the Acuson Origin ultrasound system also features the newly FDA-cleared AcuNav Lumos 4D ICE (intracardiac echocardiography) catheter.
The Food and Drug Administration (FDA) has granted 510(k) clearance for the Acuson Origin cardiovascular ultrasound system and the accompanying AcuNav Lumos 4D ICE (intracardiac echocardiography) catheter.
The Acuson Origin system reportedly bolsters workflow efficiency for transthoracic echocardiography (TTE) and transesophageal echocardiography (TEE) with over 5,600 artificial intelligence (AI) automated measurements, according to Siemens Healthineers, the manufacturer of the device.
The Acuson Origin ultrasound system reportedly bolsters workflow efficiency for transthoracic echocardiography (TTE) and transesophageal echocardiography (TEE) with over 5,600 artificial intelligence (AI ) automated measurements, according to Siemens Healthineers, the manufacturer of the device. (Image courtesy of Siemens Healthineers.)
AI Assist, one of the new TTE features for the Acuson Origin, provides automated positioning of color and spectral Doppler regions of interest. Offering real-time cardiac view recognition, Siemens Healthineers said the 4D HeartAI feature has a 98 percent accuracy for the identification and alignment of multiplanar reconstruction (MPR).
“With its advanced AI features and potential to enhance diagnostic accuracy as well as patient care, the Acuson Origin is positioned to reshape health care’s approach to cardiovascular imaging,” noted David Zollinger, the head of cardiovascular ultrasound at Siemens Healthineers.
Providing advanced imaging for complex heart procedures, Siemens Healthineers noted the AcuNav Lumos catheter promotes enhanced accuracy of anatomical assessments with MPR biplane imaging. The device’s real-time 4D color Doppler capabilities also facilitate improved leak detection, according to Siemens Healthineers.
FDA Clears Ultrasound AI Detection for Pleural Effusion and Consolidation
June 18th 2025The 14th FDA-cleared AI software embedded in the Exo Iris ultrasound device reportedly enables automated detection of key pulmonary findings that may facilitate detection of pneumonia and tuberculosis in seconds.
Ultrasound-Guided Thermal Ablation Shows Low Recurrence of Thyroid Carcinoma at Five Years
June 16th 2025In a meta-analysis involving over 2,200 patients with T1NoMo papillary thyroid carcinoma, researchers noted 2 percent recurrence and no cases of lymph node metastasis five years after ultrasound-guided thermal ablation.
Multinational Study Reaffirms Value of Adjunctive AI for Prostate MRI
June 16th 2025The use of adjunctive AI in biparametric prostate MRI exams led to 3.3 percent and 3.4 percent increases in the AUC and specificity, respectively, for clinically significant prostate cancer (csPCa) in a 360-person cohort drawn from 53 facilities.
